Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Hepatitis C Virus Replication Depends on Endosomal Cholesterol Homeostasis.

Stoeck IK, Lee JY, Tabata K, Romero-Brey I, Paul D, Schult P, Lohmann V, Kaderali L, Bartenschlager R.

J Virol. 2017 Dec 14;92(1). pii: e01196-17. doi: 10.1128/JVI.01196-17. Print 2018 Jan 1.

PMID:
29046459
2.

Genetic diversity of hepatitis C virus in Ethiopia.

Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL.

PLoS One. 2017 Jun 1;12(6):e0179064. doi: 10.1371/journal.pone.0179064. eCollection 2017.

3.

Influence of camel milk on the hepatitis C virus burden of infected patients.

El-Fakharany EM, El-Baky NA, Linjawi MH, Aljaddawi AA, Saleem TH, Nassar AY, Osman A, Redwan EM.

Exp Ther Med. 2017 Apr;13(4):1313-1320. doi: 10.3892/etm.2017.4159. Epub 2017 Feb 22.

4.

Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.

Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, Reau N, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM.

Contemp Clin Trials. 2017 Jun;57:58-68. doi: 10.1016/j.cct.2017.03.013. Epub 2017 Mar 22.

PMID:
28342989
5.

Untangling the Gordian knot of HIV, stress, and cognitive impairment.

Valdez AN, Rubin LH, Neigh GN.

Neurobiol Stress. 2016 Feb 11;4:44-54. eCollection 2016 Oct. Review.

6.

Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1.

Zhu GQ, Zou ZL, Zheng JN, Chen DZ, Zou TT, Shi KQ, Zheng MH.

Medicine (Baltimore). 2016 Mar;95(9):e3004. doi: 10.1097/MD.0000000000003004. Review.

7.

Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.

Hartman J, Bichoupan K, Patel N, Chekuri S, Harty A, Dieterich D, Perumalswami P, Branch AD.

World J Gastroenterol. 2015 Nov 21;21(43):12430-8. doi: 10.3748/wjg.v21.i43.12430.

8.

Missing the obvious: psychosocial obstacles in Veterans with hepatocellular carcinoma.

Hwa KJ, Dua MM, Wren SM, Visser BC.

HPB (Oxford). 2015 Dec;17(12):1124-9. doi: 10.1111/hpb.12508. Epub 2015 Sep 16.

9.
10.

Projections of the current and future disease burden of hepatitis C virus infection in Malaysia.

McDonald SA, Dahlui M, Mohamed R, Naning H, Shabaruddin FH, Kamarulzaman A.

PLoS One. 2015 Jun 4;10(6):e0128091. doi: 10.1371/journal.pone.0128091. eCollection 2015.

11.

Computational models of liver fibrosis progression for hepatitis C virus chronic infection.

Lara J, López-Labrador F, González-Candelas F, Berenguer M, Khudyakov YE.

BMC Bioinformatics. 2014;15 Suppl 8:S5. doi: 10.1186/1471-2105-15-S8-S5. Epub 2014 Jul 14.

12.

Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors.

Shah U, Jayne C, Chackalamannil S, Velázquez F, Guo Z, Buevich A, Howe JA, Chase R, Soriano A, Agrawal S, Rudd MT, McCauley JA, Liverton NJ, Romano J, Bush K, Coleman PJ, Grisé-Bard C, Brochu MC, Charron S, Aulakh V, Bachand B, Beaulieu P, Zaghdane H, Bhat S, Han Y, Vacca JP, Davies IW, Weber AE, Venkatraman S.

ACS Med Chem Lett. 2014 Jan 9;5(3):264-9. doi: 10.1021/ml400466p. eCollection 2014 Mar 13.

13.

Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, Ehteshami M, Schinazi RF.

Infect Drug Resist. 2014 Mar 5;7:41-56. doi: 10.2147/IDR.S36247. eCollection 2014. Review.

14.

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.

Ortega-Prieto AM, Sheldon J, Grande-Pérez A, Tejero H, Gregori J, Quer J, Esteban JI, Domingo E, Perales C.

PLoS One. 2013 Aug 16;8(8):e71039. doi: 10.1371/journal.pone.0071039. eCollection 2013.

15.

Perceptions of drug users regarding hepatitis C screening and care: a qualitative study.

Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, Guzman L, Kletter E, Seewald RM, Des-Jarlais DC, Sorensen JL, Perlman DC.

Harm Reduct J. 2013 Jun 20;10:10. doi: 10.1186/1477-7517-10-10.

16.

Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study.

El-Fakharany EM, Sánchez L, Al-Mehdar HA, Redwan EM.

Virol J. 2013 Jun 19;10:199. doi: 10.1186/1743-422X-10-199.

17.

Current and future disease progression of the chronic HCV population in the United States.

Zalesak M, Francis K, Gedeon A, Gillis J, Hvidsten K, Kidder P, Li H, Martyn D, Orne L, Smith A, Kwong A.

PLoS One. 2013 May 21;8(5):e63959. doi: 10.1371/journal.pone.0063959. Print 2013.

18.

Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J.

J Virol. 2013 Jul;87(13):7593-607. doi: 10.1128/JVI.02824-12. Epub 2013 May 1.

19.

HIV/AIDS, comorbidity, and alcohol: can we make a difference?

Justice A, Sullivan L, Fiellin D; Veterans Aging Cohort Study Project Team.

Alcohol Res Health. 2010;33(3):258-66. Review.

20.

Underestimation of liver-related mortality in the United States.

Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR.

Gastroenterology. 2013 Aug;145(2):375-82.e1-2. doi: 10.1053/j.gastro.2013.04.005. Epub 2013 Apr 9.

Supplemental Content

Support Center